No signup No ads On-device Works offline The answers people search for - on the page, where they belong
Castilla-Cortazar I, Diez N, Garcia-Fernandez M, Puche JE, Diez-Caballero F, Quiroga J, Diaz-Sanchez M, Castilla A, Casares AD, Varela-Nieto I: Hematotesticular barrier is altered from early stages of liver cirrhosis: effect of insulin-like growth factor 1
doi:10.1111/cea.13309
Stop and Seek Help If Any signs of allergic reactionhives, swelling, breathing difficulty (stop immediately, seek help) Severe or persistent headaches that don't respond to dose reduction Excessive daytime drowsiness affecting your ability to function Unusual mood changes or psychological symptoms You've completed your planned cycle (typically 4-6 weeks) Your healthcare provider recommends discontinuation DSIP is a research peptide, not an FDA-approved medication
IGF-1 receptors undergo ligand-induced downregulation: prolonged exposure to elevated IGF-1 LR3 concentrations triggers receptor internalization, ubiquitination, and lysosomal degradation, reducing cell surface receptor density by 3050% within 34 weeks of continuous daily dosing in myocyte culture models
